RSS Feed
- Netflix: The Biggest Empty Promise Since Enron?
- Why Car Prices Vary From City To City
- Big Bank Phobia: Not Too Big to Fail
- Expect Your Health Care in Retirement to Hit $200,000
- Apple Should Still Fire Tim Cook
Article
Repros Patent Problems Began When Harry Met Joe
A New York fertility doctor accuses Repros CEO of stealing the idea for a new oral testosterone therapy.
08:00AM 05/09/13
Article
Amarin Trouble Grows As Does Evidence Against Fish Oil's Benefits
Fish oil supplements have no heart benefits for patients, which doesn't bode well for Amarin's efforts to market Vascepa.
12:15AM 05/09/13
Article
Osiris CEO: Our Stem Cell Drug With Zero Sales Is Widely Used
Osiris CEO claims Prochymal is most widely used stem cell drug in world yet has generated no sales -- ever.
01:19PM 05/07/13
Article
Happy Day for Arena Bulls, Bears as Belviq Launch Finally Arrives
DEA finalizes Belviq abuse schedule, allowing the weight-loss pill launch in June.
11:53AM 05/07/13
Article
Fire Aveo's CEO for Incompetence and Arrogance Rivaling ImClone's Sam Waksal
Heads need to roll at Aveo because of the FDA's thrashing of the company's kidney cancer drug.
12:26PM 05/06/13
Article
Leaders of TheStreet's Drug Approval Contest
This group of contestants have nearly perfect records picking FDA and European drug approvals.
09:21AM 05/06/13
Article
Aveo, Delcath FDA Panel Live Blog
Join TheStreet's Adam Feuerstein as he live blogs FDA advisory panels for Aveo Oncology and Delcath Systems
07:44AM 05/02/13
Article
An Outrageous, Shameless Act by Hemispherx's Board of Directors
Hemispherx CEO earns a bonus for overseeing the sale of company stock.
12:03PM 05/01/13
Article
FDA Rejection of Titan's Probuphine Looks Like a Mugging
FDA find much at fault with Titan's implantable therapy for opioid dependence.
10:19AM 05/01/13
Article
Raptor's FDA Approval Is New Test for Orphan Drug Pricing
Will insurers pay more for a orphan disease drug only because it's more convenient?
07:51AM 05/01/13